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Supplementary Table 1: Overall statistical analysis of the neurogenic effects of S 
38093 in 129/SvEv Tac mice. 
 
 
Supplementary Table 2: Overall statistical analysis of the neurogenic effects of S 
38093 in 3-month old or 16-month old C57BL/6JRj mice. 
 
 
Supplementary Table 3: Overall statistical analysis of the neurogenic effects of S 
38093 in APPSWEWT and APPSWTg mice. 
 
 
Supplementary Table 4: Overall statistical analysis of the effects of S 38093 on 
dendritic arborization in APPSWEWT and APPSWTg mice. 
 
 
Supplementary Table 5: Overall statistical analysis of the effects of S 38093 on 
gene expression in 3-month old or 16-month old C57BL/6JRj mice. 
 
 
Supplementary Table 6: Statistical analysis of the effects of aging and S 38093 on 
context discrimination in 3-month old or 16-month old C57BL/6JRj mice. 
 
Neurogenic and behavioral effects of S38093 – Supplementary Information Page 3/6 
Supplementary Table 7: Statistical analysis of the effects of aging and S 38093 on 
discrimination ratio in 3-month old or 16-month old C57BL/6JRj mice. 
 
Supplementary Figure 1: Timeline of experiments 
Effects of chronic S 38093 administration on neurogenesis were tested in 3-month-old 
129/SvEv Tac mice (S1A). BrdU (150 mg/kg, i.p.) was injected twice a day for 3 days 
before the start of treatment, or 2 hours before sacrifice of the animals, at the end of the 
treatment. Neurogenic effects of S 38093 (0.3 and 3 mg/kg/d) were compared to a 4-
week fluoxetine (18 mg/kg/d). 
 
Effects of aging and chronic S 38093 administration on neurogenesis were tested in 3 
and 16-month-old C57BL/6JRj mice at the start of the experiment (S1B). BrdU (150 
mg/kg, i.p.) was injected twice a day for 3 days before the start of treatment. Neurogenic 
effects of S 38093 (0.3, 1 and 3 mg/kg/d) were compared to a 4-week donepezil (0.3 or 
1 mg/kg/d) treatment.  
 
Neurogenic effects of chronic administration of S 38093 (3 mg/kg/d, 28 days) were 
tested in the APPSWE mouse model of Alzheimer’s Disease (S1C). BrdU (150 mg/kg, 
i.p.) was injected twice a day for 3 days before the start of treatment.  
 
Behavioral effects of aging or chronic S 38093 administration (0.3 and 3 mg/kg/d, 28 
days) were tested in 16-month-old C57BL/6JRj mice (S1D). Pattern Discrimination 
protocol was performed after 4 weeks of chronic treatment, during day 29 to 36. 
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Supplementary Figure 2: Chronic S 38093 administration enhances adult 
hippocampal neurogenesis along the septotemporal axis of the dentate gyrus of 
young adult 129/SvEvTac mice. 
The effects of chronic administration of S 38093 (0.3 and 3 mg/kg/day p.o., 28 days) and 
fluoxetine (18 mg/kg/day p.o., 28 days) on cell proliferation (S2A, B), survival (S2C, D) 
and maturation (S2E, F) were compared to those of vehicle (purified water) along the 
septotemporal axis of the hippocampus. Cell proliferation (S2A, B) and survival (S2C, D) 
were expressed by the number of BrdU+ cells. Maturation was represented by the total 
number of DCX+ cells with tertiary dendrites (S2E, F). Data are expressed as mean ± 
SEM. A one-way ANOVA was applied to the data followed by Fisher’s PLSD post hoc 
analysis as appropriate. *p<0.05, **p<0.01 compared to vehicle (n=5-10 mice of 3 
months old per group).  
 
 
Supplementary Figure 3: Effects of chronic S 38093 administration on dendritic 
maturation in the dentate gyrus of the hippocampus in the APPSWE model of 
Alzheimer’s disease 
The effects of chronic treatment with S 38093 (3 mg/kg/d, 28 days) on dendritic 
complexity were compared to those of vehicle in APPSWEWT and APPSWETg mice. The 
effects of tested treatments on dendritic length (S3A, C) and the number of intersection 
(S3B, D) were measured (n=3 mice/group, 20 cells/mouse) using a Sholl analysis of 
DCX+ neurons in APPSWEWT and APPSWETg mice. A two-way ANOVA with repeated 
measures was applied to the data. Significant main effects and/or interactions were 
followed by Fisher’s PLSD post hoc analysis. *p<0.05, **p<0.01 and ***p<0.001 for 
effects of S 38093 compared to vehicle. Representative image and traces from Sholl 
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analyses of DCX+ cells with tertiary branches after vehicle or chronic S 38093 in 
APPSWEWT and APPSWETg (S3E). 
 
 
Supplementary Figure 4: Representative illustrations of doublecortin (DCX) 
immunoreactive positive cells (10x magnification) in the dentate gyrus after 4 
weeks of treatment with vehicle (S4A, 4E), fluoxetine (18 mg/kg/d) (S4B, 4F), S 
38093 (0.3 or 3 mg/kg/d) (S4C, D, 4G, H) along the dorso/ventral axis in adult 
129/SvEv Tac mice. Scale bar = 100µm. 
 
 
Supplementary Figure 5: Representative illustrations of confocal BrdU 
immunoreactive positive cells alone (S5A), colocalized with doublecortin (DCX) 
(S5B), colocalized with DCX and NeuN (S5C), or colocalized with NeuN (S5D) (63x 
magnification) in the dentate gyrus in 129/SvEv Tac mice. 
 
 
Supplementary Figure 6: Representative illustrations of Ki67+ (S6A, 6B) or 
doublecortin (DCX) (S6C, 6D) immunoreactive positive cells (10x magnification) in 
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Supplementary Figure 7: Representative illustrations of doublecortin (DCX) (S7C, 
7D) immunoreactive positive cells (10x magnification) in the dentate gyrus in 
APPSWEWT and APPSWETg after 4 weeks of treatment with S 38093 (3 mg/kg/d). 
Scale bar = 100µm. 
 
 
Supplemental movie 1: Reconstruction of z-stack of BrdU+ cells colocalized with 
DCX+ cells in the dentate gyrus in 129/SvEv Tac strain taken with a Zeiss LSM 510 
confocal microscope (63x magnification) using Imaris 7.8. 
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3, 30 5.429 0.0073 0.0036 0.0827 0.0021 0.1761 0.9253
1B Survival BrdU positive 
cells (survival)
3, 31 4.691 0.0082 0.0077 0.0054 0.0017 0.8803 0.3866
1C Maturation Total DCX 
Cells
3, 22 1.656 0.2055
1D Maturation
DCX cells with 
tertiary 
dendrites
3, 22 4.119 0.0184 0.0047 0.0246 0.3907 0.3536 0.0281
1E Maturation Maturation 
Index




























3, 31 3.4778 0.0276 0.0059 0.0175 0.0211 0.6408 0.7718
S2E Maturation 
Dorsal
DCX cells with 
tertiary 
dendrites
3,22 5.867 0.0042 0.0007 0.0121 0.1885 0.1603 0.0128
S2F Maturation 
Ventral
DCX cells with 
tertiary 
dendrites
3, 31 3.4778 0.0276 0.0059 0.0175 0.0211 0.6408 0.7718



































































































































































































2A Proliferation Ki67 positive cells (proliferation) 5, 20 3.183 0.0283 0.1504 0.1321 0.0242 0.0048 0.0037 0.276 0.1049 0.1012 0.4612 0.2352 0.2411 <0.0001
2B Survival BrdU positive cells (survival) 5, 32 4.545 0.003 0.9674 0.0839 0.2033 0.0185 0.0002 0.2842 0.0531 0.0016 0.8394 0.5046 0.0258 <0.0001
2C Maturation Total DCX Cells 5, 28 3.223 0.0201 0.4252 0.1838 0.655 0.6215 0.0215 0.3025 0.8402 0.0049 0.1518 0.5105 0.0012 <0.0001
2D Maturation DCX cells with tertiary dendrites 5, 28 6.66 0.0003 0.8706 0.3128 0.4766 0.957 0.0002 0.4211 0.9321 0.0002 0.1511 0.4257 < 0.0001 <0.0001
2E Maturation Maturation Index 5, 28 3.44 0.0151 0.5224 0.8111 0.4629 0.6809 0.0014 0.8291 0.8836 0.0126 0.3774 0.5558 0.0015 <0.0001
2F Cell differentiation Relative proportion of BrdU+/NeuN+ cells 5, 22 2.752 0.046 0.2764 0.9898 0.8237 0.0536 0.0408 0.2034 0.0088 0.0105 0.8336 0.055 0.0622 <0.0001




















































































































































APPSWE-WT/APPSWE-Tg Proliferation Ki67 positive cells (proliferation) 1, 34 0.1200 0.7312 6.568 0.015 0.003874 0.950
APPSWE-WT/APPSWE-Tg Survival BrdU positive cells (survival) 2, 30 10.94 0.0024 22.16 0.0001 7.339 0.011 0.12 <0.0001
APPSWE-WT/APPSWE-Tg Maturation Total DCX Cells 2, 35 0.8823 0.3540 4.923 0.0331 0.1081 0.7443
APPSWE-WT/APPSWE-Tg Maturation DCX cells with tertiary dendrites 2, 35 2.329 0.136 6.700 0.0139 0.1701 0.6825
APPSWE-WT/APPSWE-Tg Maturation Maturation Index 2, 35 5.92 0.0202 9.164 0.0046 0.9852 0.3277

























































































































































































































































3A Maturation Dendritic Length in WT 1, 58 6.407 0.0141 19, 1102 76.53 <0.0001 19, 1102 0.9388 0.5338
3A Maturation Dendritic Length at 10µm
3A Maturation Dendritic Length at 20µm
3A Maturation Dendritic Length at 30µm
3A Maturation Dendritic Length at 40µm
3A Maturation Dendritic Length at 50µm
3A Maturation Dendritic Length at 60µm
3A Maturation Dendritic Length at 70µm
3A Maturation Dendritic Length at 80µm
3A Maturation Dendritic Length at 90µm
3A Maturation Dendritic Length at 100µm
3A Maturation Dendritic Length at 110µm
3A Maturation Dendritic Length at 120µm
3A Maturation Dendritic Length at 130µm
3A Maturation Dendritic Length at 140µm
3A Maturation Dendritic Length at 150µm
3A Maturation Dendritic Length at 160µm
3A Maturation Dendritic Length at 170µm
3A Maturation Dendritic Length at 180µm
3A Maturation Dendritic Length at 190µm
3A Maturation Dendritic Length at 200µm
Supplementary Figure 3B
3B Maturation Dendritic Intersection in WT 1, 58 3.201 0.0788 19, 1102 75.89 <0.0001 19, 1102 0.4623 0.9764
3B Maturation Dendritic Intersection at 10µm
3B Maturation Dendritic Intersection at 20µm
3B Maturation Dendritic Intersection at 30µm
3B Maturation Dendritic Intersection at 40µm
3B Maturation Dendritic Intersection at 50µm
3B Maturation Dendritic Intersection at 60µm
3B Maturation Dendritic Intersection at 70µm
3B Maturation Dendritic Intersection at 80µm
3B Maturation Dendritic Intersection at 90µm
3B Maturation Dendritic Intersection at 100µm
3B Maturation Dendritic Intersection at 110µm
3B Maturation Dendritic Intersection at 120µm
3B Maturation Dendritic Intersection at 130µm
3B Maturation Dendritic Intersection at 140µm
3B Maturation Dendritic Intersection at 150µm
3B Maturation Dendritic Intersection at 160µm
3B Maturation Dendritic Intersection at 170µm
3B Maturation Dendritic Intersection at 180µm
3B Maturation Dendritic Intersection at 190µm
3B Maturation Dendritic Intersection at 200µm
Supplementary Figure 2C
2C Maturation Dendritic Length in Tg 1, 58 7.553 0.0080 19, 1102 105.7 <0.0001 19, 1102 2.426 0.0006
2C Maturation Dendritic Length at 10µm 0.9246
2C Maturation Dendritic Length at 20µm 0.6095
2C Maturation Dendritic Length at 30µm 0.1037
2C Maturation Dendritic Length at 40µm 0.0014
2C Maturation Dendritic Length at 50µm < 0.0001
2C Maturation Dendritic Length at 60µm < 0.0001
2C Maturation Dendritic Length at 70µm 0.0005
2C Maturation Dendritic Length at 80µm 0.0332
2C Maturation Dendritic Length at 90µm 0.3252
2C Maturation Dendritic Length at 100µm 0.451
2C Maturation Dendritic Length at 110µm 0.7285
2C Maturation Dendritic Length at 120µm 0.7259
2C Maturation Dendritic Length at 130µm 0.7101
2C Maturation Dendritic Length at 140µm 0.7594
2C Maturation Dendritic Length at 150µm 0.8903
2C Maturation Dendritic Length at 160µm 0.9888
2C Maturation Dendritic Length at 170µm > 0.9999
2C Maturation Dendritic Length at 180µm > 0.9999
2C Maturation Dendritic Length at 190µm > 0.9999
2C Maturation Dendritic Length at 200µm > 0.9999
Supplementary Figure 2D
2D Maturation Dendritic Intersection in Tg 1, 58 3.614 <0.0001 19, 1102 70.05 <0.0001 19, 1102 2.467 0.0005
2D Maturation Dendritic Intersection at 10µm 0.8996
2D Maturation Dendritic Intersection at 20µm 0.6741
2D Maturation Dendritic Intersection at 30µm 0.5476
2D Maturation Dendritic Intersection at 40µm 0.671
2D Maturation Dendritic Intersection at 50µm 0.018
2D Maturation Dendritic Intersection at 60µm 0.0003
2D Maturation Dendritic Intersection at 70µm 0.0007
2D Maturation Dendritic Intersection at 80µm 0.0135
2D Maturation Dendritic Intersection at 90µm 0.883
2D Maturation Dendritic Intersection at 100µm 0.6926
2D Maturation Dendritic Intersection at 110µm 0.5064
2D Maturation Dendritic Intersection at 120µm 0.4171
2D Maturation Dendritic Intersection at 130µm 0.1494
2D Maturation Dendritic Intersection at 140µm 0.2276
2D Maturation Dendritic Intersection at 150µm 0.4004
2D Maturation Dendritic Intersection at 160µm 0.7208
2D Maturation Dendritic Intersection at 170µm 0.7176
2D Maturation Dendritic Intersection at 180µm 0.9029
2D Maturation Dendritic Intersection at 190µm > 0.9999
2D Maturation Dendritic Intersection at 200µm > 0.9999







































































































3A BDNF exon I Average expression level 6, 35 3.464 0.0086 0.004 0.3246 0.3421 0.1156 0.0053 0.0014
3B BDNF exon IV Average expression level 6, 44 4.571 0.0011 0.0208 0.3401 0.999 0.0758 0.8695 0.0208
3C BDNF exon VI Average expression level 6, 45 0.7969 0.5788
3D BDNF exon IX Average expression level 6, 44 6.559 <0.0001 0.0134 0.0237 0.1745 0.8548 0.0325 0.0134
3E VEGFA Average expression level 6, 44 2.049 0.0791
3F IGF1 Average expression level 6, 44 1.502 0.1999
3G H3 receptor Average expression level 2, 13 0.07371 0.9293 0.8276 0.8616 0.7079














































































































































































































































































































































4B Contextual Fear Conditionning Young Freezing (%) 1 14 125.0 <0.0001 9 126 4.190 <0.0001 9 126 3.948 0.0002 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0,0001 < 0,0001
4C Contextual Fear Conditionning Old Freezing (%) 1 14 25.82 0.0002 9 126 5.913 <0.0001 9 126 4.768 <0.0001 0,6383 0,1247 0,0322 0,0208 0,0221 0,0629 0,1119 0,0666 < 0,0001 < 0,0001
4D Contextual Fear Conditionning Discrimination Ratio 2 26 14.35 <0.0001 10 260 1.969 0.0369 10 260 2.179 0.0031 0.2147 0.0131 <0.0001 0.0016 <0.0001 0.0349 <0.0001 <0.0001 0.0004 0.0003
4F Contextual Fear Conditionning Vehicle Freezing (%) 1 11 16.41 0.0019 5 55 0.9565 0.4524 5 55 3.5000 0.0081 0,6813 0,8945 0,8606 0,673 0,0019 < 0,0001
4G Contextual Fear Conditionning Low Dose Freezing (%) 1 12 34.96 <0.0001 5,0000 60,0000 0.8362 0.5293 5 60 5.880 0.0002 0,5226 0,2222 0,0013 0,0086 < 0,0001 < 0,0001
4H Contextual Fear Conditionning High Dose Freezing (%) 1 13 23.35 0.0003 5,0000 65,0000 0.7400 0.5962 5 65 1.075 0.3826

































































































































































































































































4I Contextual Fear Conditionning Discrimination Ratio 2 36 2.107 0.1363 5,0000 180,0000 7.277 <0.0001 10 180 1.041 0.4113 0.4658 0.3968 0.0372 0.1183 0.1715 0.7978
